68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging
The Journal of Clinical Endocrinology & Metabolism · 16.10.2026 · 111 (11) · 3163-3171
DOI: 10.1210/clinem/dgag214 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.05.2026. Verfasst von Julia G Fricke und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland. Hauptthemen laut MEDLINE: Insulinoma, Positron Emission Tomography Computed Tomography, Pancreatic Neoplasms, Exenatide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Insulinomas are the main cause of endogenous hyperinsulinemic hypoglycemia (EHH) in adults, with surgery as the only cure. Pancreas-preserving surgery is preferred, making precise preoperative localization crucial. GLP-1R-targeted imaging, such as [68Ga]Ga-DOTA-exendin-4 PET/CT, outperforms other imaging procedures for insulinoma localization.
Objective
To investigate the performance and clinical impact of [68Ga]Ga-DOTA-exendin-4 PET/CT for the detection of insulinomas in patients with EHH and prior negative or inconclusive conventional imaging.
Methods
In this retrospective, real-world, dual-center imaging study, 101 patients with biochemically proven EHH and/or a positive Whipple's triad underwent [68Ga]Ga-DOTA-exendin-4 PET/CT at two tertiary centers between April 2017 and March 2024. Among these, 58 patients with prior negative or inconclusive conventional imaging constituted the primary analysis cohort. Endpoints: Insulinoma detection rate and sensitivity by [68Ga]Ga-DOTA-exendin-4 PET/CT after negative or inconclusive conventional imaging and impact on clinical management.
Results
Among the 58 patients with prior negative or inconclusive conventional imaging, [68Ga]Ga-DOTA-exendin-4 PET/CT was positive in 42 patients, corresponding to a detection rate of 72% (95% CI, 59-83%). Thirty patients subsequently underwent PET/CT-guided surgery. Overall, 32 patients had histological verification (including two PET/CT-negative cases), corresponding to a sensitivity of 93.8% (95% CI, 79-99%).
Conclusion
In real-world clinical practice, [68Ga]Ga-DOTA-exendin-4 PET/CT provides a high detection rate of 72% for localizing insulinomas, including one case of diffuse nesidioblastosis in patients with EHH and prior negative or inconclusive conventional imaging, thereby enabling PET/CT-guided surgical approaches. These findings underscore the substantial clinical impact of GLP-1R-targeted PET/CT on patient management and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland.
- Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- Berta-Ottenstein Program, Faculty of Medicine University of Freiburg, 79106 Freiburg, Germany.
- Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, 4031 Basel, Switzerland.
ORCID-Profile: Julia G Fricke, Damian Wild, Emanuel Christ
Zitieren
APA
Fricke, J. G., Laubner, K., Schildmeijer, M., Menz, L., Wojsa, C., Meyer, P. T., Seufert, J., Wild, D., Christ, E., & Freitag, M. T. (2026). 68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging. The Journal of Clinical Endocrinology & Metabolism, 111(11), 3163-3171. https://doi.org/10.1210/clinem/dgag214
Vancouver
Fricke JG, Laubner K, Schildmeijer M, Menz L, Wojsa C, Meyer PT, et al. 68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging. The Journal of Clinical Endocrinology & Metabolism. 2026;111(11):3163-3171. doi:10.1210/clinem/dgag214
BibTeX
@article{Fricke2026,
author = {Fricke, Julia G and Laubner, Katharina and Schildmeijer, Manuela and Menz, Lea and Wojsa, Camilla and Meyer, Philipp T and Seufert, Jochen and Wild, Damian and Christ, Emanuel and Freitag, Martin T},
title = {68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {11},
pages = {3163--3171},
doi = {10.1210/clinem/dgag214}
}
EUVIMED